scPharmaceuticals (US:SCPH)2025-06-23 11:27Financial Performance & Position - FUROSCIX achieved $12.2 million in Q4 2024 net revenue, a 21% sequential increase from Q3 2024[7,47] - Full Year 2024 net revenue reached $36.3 million, up 167% from Full Year 2023[7,47] - The company held $75.7 million in cash and cash equivalents as of year-end 2024[8] FUROSCIX & Market Opportunity - FUROSCIX is indicated for congestion due to fluid overload in adult patients with chronic heart failure, delivering 80 mg/10 mL dose over 5 hours with 99.6% bioavailability[16] - The addressable US market opportunity for heart failure is estimated at $9.9 billion[11,39] - The average cost of a heart failure hospitalization is $11,840, with heart failure patients representing 33% ($123B) of annual Medicare Part A and B spending[25] Clinical Study Results - The AT HOME-HF Study showed FUROSCIX subjects demonstrated augmented decongestion vs enhanced oral diuretics, with a 37% relative risk reduction in heart failure hospitalizations[21,23] - The Autoinjector PK/PD study achieved a bioavailability of 107.3% (90% CI: 103.9 – 110.8) compared to IV furosemide[84] Long-Term Growth Initiatives - The company received FDA approval for expanded FUROSCIX indication to include NYHA Class IV heart failure patients on August 9, 2024, representing approximately 10% of all heart failure patients[58,59] - The company received FDA approval for Chronic Kidney Disease indication on March 6, 2025, with launch planned in April 2025[9,57] - The addressable market opportunity for Chronic Kidney Disease is estimated at $3.32 billion, targeting 0.7 million FUROSCIX addressable CKD fluid events[75] - The company is targeting an sNDA submission to the FDA for the 80mg/1mL FUROSCIX Autoinjector in 2025, which could reduce COGS by approximately 70%[9,56,82]